Amgen 2007 Annual Report Download - page 36

Download and view the complete annual report

Please find page 36 of the 2007 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 180

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180

The following provides additional information on competition related to our principal products and other se-
lected products and product candidates in the therapeutic area(s) in which we market or expect to market them.
Supportive cancer care
Any products or technologies that are directly or indirectly successful in addressing anemia associated with
chemotherapy could negatively impact product sales for Aranesp®. Neulasta®and NEUPOGEN®could face
competition in some circumstances from companies marketing or developing treatments for neutropenia asso-
ciated with chemotherapy, for bone marrow and PBPC transplant patients, and AML.
NEUPOGEN®competes with Neulasta®in the United States and Europe. U.S. and international NEUP-
OGEN®sales have been adversely impacted by conversion to Neulasta®. However, we believe that most of the
conversion in the United States and Europe had already occurred by December 31, 2007.
The following table reflects companies and their currently marketed products that primarily compete with
Aranesp®, Neulasta®and NEUPOGEN®in the United States and internationally in the supportive cancer care
segment.
Amgen Marketed Product Competitor Marketed Product Competitor
Aranesp®— U.S. PROCRIT®J&J
Aranesp®— International EPREX®/ ERYPO®Janssen-Cilag(1)
Aranesp®— International NeoRecormon®Roche
Aranesp®— International Retacrit™(2) / Silapo®(2) Hospira Enterprise B.V.
(“Hospira”) / Stada Arzneimittel
AG (“Stada”)
Aranesp®— International Binocrit®(2) / Epoetin Alpha
Hexal®(2) / Abseamed®(2)
Sandoz GmbH (“Sandoz”) / Hexal
Biotech Forschungs GmbH
(“Hexal”)/ Medice Arzneimittel
Pütter GmbH & Co. KG
(“Medice”)
Neulasta®/NEUPOGEN®— U.S. Leukine®Bayer HealthCare Pharmaceuticals
Neulasta®/NEUPOGEN®— U.S. Ethyol®MedImmune Oncology, Inc.
Neulasta®/NEUPOGEN®—
International
Granocyte®Chugai Pharmaceuticals Co., Ltd. /
Sanofi-Aventis
Neulasta®/NEUPOGEN®—
International
Leucomax®Novartis AG (“Novartis”)
Neulasta®/NEUPOGEN®—
International
Neu-up®Kyowa Hakko Kogyo Co., Ltd.
(1) A subsidiary of J&J.
(2) Biosimilar products that were approved and launched in certain EU countries in 2007.
In addition to competition from the above-noted products, Affymax Inc. (“Affymax”)/Takeda are
co-developing, Hematide™, an erythropoietin mimetic for the treatment of anemia. Although we cannot predict
with certainty when the first G-CSF biosimilar products could appear on the market in the EU, with the Febru-
ary 21, 2008 positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”), we expect
that the first G-CSF biosimilar product will be approved in the EU in the first half of 2008 and could be available
shortly thereafter, and that it would compete with Neulasta®and NEUPOGEN®.
Nephrology
Any products or technologies that are directly or indirectly successful in addressing anemia associated with
CRF could negatively impact product sales for Aranesp®and EPOGEN®. In the United States, Aranesp®and
EPOGEN®compete with each other, primarily in the U.S. hospital dialysis clinics and there was a conversion
from EPOGEN®to Aranesp®in this setting, however we believe that the conversion has stabilized.
24